Print Page  |  Close Window

Investors

FGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$24.80
Change (%) Stock is Down 0.25 (1.00%)
Volume298,852
Data as of 03/24/17 4:00 p.m. ET
Refresh quote
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.
Recent Press ReleasesMore »
DateTitle 
03/01/17FibroGen Reports Fiscal 2016 Financial ResultsPrinter Friendly Version
02/22/17FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017Printer Friendly Version
02/03/17FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with ChemotherapyPrinter Friendly Version
01/30/17FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in ChinaPrinter Friendly Version
Upcoming EventsMore »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources